



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BioMark Receives No Objection Letter From Health Canada

Vancouver, British Columbia – (May 26, 2015) – BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTCQB : BMKDF) is pleased to announce that it has received a no objection letter (“NOL”) to extend its trials in both Canada and Bangladesh from Health Canada’s Office of Clinical Trials.

Rashid Ahmed, President and CEO, comments: “This marks another milestone for BioMark and allows the company to gather more representative data for analytical purposes especially for the types of cancers that BioMark is currently building its diagnostics and screening applications and platform for. Following Health Canada clearance, the extended trials will allow BioMark to gather more data, which can potentially allow BioMark to demonstrate the efficacy of its cancer diagnostic tests that we believe has significant medical, patient and commercial opportunity”.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer, early and cost effectively. BioMark is currently conducting multi site clinical trials for lung, breast, gastro intestinal and prostate cancers. Additionally trials related to assess response to lung cancer treatment and surgical interventions are being established.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

For further information on BioMark, please Contact:

Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-282-6567
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Biomark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue

reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.